{"uid":"cap_0ztY6H2yNwfbOG30IAuHH","slug":"clinicalintelpulse-mechanism-map-9845f981","name":"ClinicalIntelPulse Mechanism Map","description":"Drug mechanism-of-action + molecular target landscape for any disease — targets in active trials, approved agents by MOA, crowded vs novel mechanisms and first-in-class openings, with key publications. Worldwide. For drug-discovery and VC agents.","url":"https://clinicalintelpulse.vercel.app/api/clinical/mechanism-map","method":"GET","headers":{},"bodySchema":{"type":"object","$schema":"https://json-schema.org/draft/2020-12/schema","required":["input"],"properties":{"input":{"type":"object","required":["type","method"],"properties":{"type":{"type":"string","const":"http"},"method":{"enum":["GET","HEAD","DELETE"],"type":"string"},"queryParams":{"type":"object","properties":{"lang":{"type":"string"},"condition":{"type":"string"},"mechanism":{"type":"string"}}}},"additionalProperties":false},"output":{"type":"object","required":["type"],"properties":{"type":{"type":"string"},"errors":{"type":"object","description":"Documented error responses, keyed by HTTP status code","additionalProperties":{"type":"object","required":["description"],"properties":{"example":{"type":"object"},"description":{"type":"string"}}}},"example":{"type":"object"}}}}},"responseSchema":{"type":"json","example":{"query_summary":{"condition":"Multiple Sclerosis","mechanism":null},"key_publications":[{"year":"2024","title":"BTK inhibitors in progressive MS — mechanisms and clinical data","journal":"Nature Reviews Neurology"}],"mechanism_landscape":{"white_spaces":["Progressive MS neuroprotection","Remyelination","CNS innate immunity","Biomarker-stratified precision approaches"],"crowded_spaces":["Anti-CD20 (3 approved, 2 in pipeline)","S1P modulators (4 approved)","Natalizumab analogues"],"approved_mechanisms":[{"moa":"Anti-CD20 (B cell depletion)","drugs":["Ocrelizumab","Ofatumumab","Ublituximab"],"notes":"Dominant mechanism for RRMS — 3 approved"},{"moa":"S1P receptor modulator","drugs":["Fingolimod","Siponimod","Ozanimod","Ponesimod"],"notes":"Oral DMT — 4 approved; class mature"},{"moa":"BTK inhibitor","drugs":[],"notes":"No approvals yet — 6 agents in Phase 2/3"}],"pipeline_mechanisms":[{"moa":"BTK inhibition (CNS-penetrant)","phase":"PHASE3","agents":["Fenebrutinib (Roche)","Tolebrutinib (Sanofi)","Evobrutinib (Merck)"],"crowding":"Moderate (3 Phase 3)","differentiation":"Targets microglial activation — may address progressive MS unlike existing agents"},{"moa":"Remyelination (opioid receptor modulation)","phase":"PHASE2","agents":["Opicinumab (Biogen)"],"crowding":"Low","differentiation":"Novel — no approved remyelinating agents"}]},"drug_discovery_implications":"BTK inhibition is the most clinically advanced novel mechanism. CNS penetration and microglial targeting differentiate from older agents. Progressive MS remains the largest unmet need.","first_in_class_opportunities":["BTK inhibitors for progression (if Phase 3 data positive)","Remyelinating agents (no approved class)"]}},"example":null,"exampleRequest":null,"tags":["x402"],"displayCostAmount":"0.2","displayCostAsset":"USDC","priceDynamic":false,"priceHint":null,"priceStatus":"priced","priceSource":"probe","requiresHandshake":false,"reviewCount":0,"rating":{"score":"0.00","successRate":"0.00","reviews":0,"stars":null,"state":"unrated"},"availabilityStatus":"unknown","priceObserved":null,"sessionDeposit":null,"pricing":{"kind":"static","summary":"$0.2/call","primary":{"kind":"static","protocol":"x402","network":"base","amountUsd":"0.2","per":"call","confidence":"exact"},"accepted":[{"kind":"static","protocol":"x402","network":"base","amountUsd":"0.2","per":"call","confidence":"exact"}]},"paymentMethods":[{"uid":"pm_kFrFqdxF30myF9koZ2xUu","protocol":"x402","methodType":"crypto","chain":"base","mode":"charge","costAmount":"0.2","costPer":"request","priority":0,"asset":"0x833589fCD6eDb6E08f4c7C32D4f71b54bdA02913","unit":"request","depositMicros":null,"planRef":null}],"brandName":null,"brandSlug":null,"brandBaseUrl":null,"brandDocsUrl":null,"whatItDoes":"Returns the molecular target and mechanism-of-action landscape for a disease, including targets in active trials, approved agents by MOA, crowded vs. novel spaces, and first-in-class openings.","exampleAgentPrompt":"Can you pull the mechanism-of-action landscape for NASH — I want to see which molecular targets are in active trials, which MOAs already have approved drugs, and where the first-in-class white-space opportunities are?","exampleUseCases":null,"resultDescription":"A structured map of molecular targets and MOAs for the queried disease: which targets are pursued in active trials, approved agents organized by mechanism, identification of crowded MOA spaces vs. novel/underpopulated ones, and highlighted first-in-class openings for drug discovery or investment.","failureModes":["Unknown or misspelled disease name returns empty or error response","Very rare diseases may have sparse data and limited MOA coverage","Rate limiting or payment failure (x402) if USDC balance is insufficient","Ambiguous disease names (e.g. 'cancer') may require more specific input"],"whenToPreferThis":"Use this endpoint when you need a strategic MOA-level view of a disease area for drug discovery, competitive intelligence, or VC due diligence — specifically when you want to understand which molecular targets are actively pursued vs. novel, and where first-in-class opportunities exist. Prefer this over the broader pipeline endpoint when the specific focus is on mechanism-of-action mapping rather than trial counts or sponsor landscape.","instructions":null,"reviewSummary":null,"reviewSummaryHighlights":null,"reviewSummaryConcerns":null,"reviewSummaryGeneratedAt":null,"activationCount":0,"lastUsedAt":null,"lastSuccessfullyRanAt":null,"lastHealthCheckAt":"2026-09-13T12:42:02.203Z","isFirstParty":false}